Trial Profile
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- Sponsors Seagen; Seattle Genetics
- 21 Jun 2020 Results assessing Impact of Nivolumab on Overall Survival in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from two clinical studies presented at the 25th Congress of the European Haematology Association
- 15 May 2020 According to a Takeda China media release, ADCETRIS (brentuximab vedotin) has been officially approved by Chinas National Medical Products Administration (NMPA) for use in adult patients with relapsed or refractory systemic Anaplastic Large Cell Lymphoma (sALCL) or CD30-positive Hodgkin Lymphoma. The local approval of ADCETRIS in China is based on the data from clinical studies SG035-0004, SG035-0003 and C25007.
- 06 Nov 2019 Results of MAIC analysis (matching adjusted indirect comparison) of two clinical trials CheckMate 205 or NCT02181738 (n=306) and NCT00848926 (n=102) assesing efficacy and survival benefit of nivolumab relative to Brentuximab vedotin in relapsed/refractory classical hodgkin lymphoma, released in 61st Annual Meeting and Exposition of the American Society of Hematology